{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T12:25:16Z","timestamp":1793967916397,"version":"4.8.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,11,21]],"date-time":"2019-11-21T00:00:00Z","timestamp":1574294400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,11,21]],"date-time":"2019-11-21T00:00:00Z","timestamp":1574294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Proton-pump inhibitors, PPIs, are considered effective therapy for stomach acid suppression due to their irreversible inhibition of the hydrogen\/potassium pump in the gastric parietal cells. They are widely prescribed and are considered safe for over-the-counter use. Recent studies have shown an association between PPI use and Alzheimer dementia, while others have disputed that connection. We analyzed over ten million United States Food and Drug Administration Adverse Event Reporting System reports, including over forty thousand reports containing PPIs, and provided evidence of increased propensity for memory impairment among PPI reports when compared to histamine-2 receptor antagonist control group. Furthermore, we found significant associations of PPI use with a wide range of neurological adverse reactions including, migraine, several peripheral neuropathies, and visual and auditory neurosensory abnormalities.<\/jats:p>","DOI":"10.1038\/s41598-019-53622-3","type":"journal-article","created":{"date-parts":[[2019,11,21]],"date-time":"2019-11-21T11:02:41Z","timestamp":1574334161000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":61,"title":["Proton-pump inhibitor use is associated with a broad spectrum of neurological adverse events including impaired hearing, vision, and memory"],"prefix":"10.1038","volume":"9","author":[{"given":"Tigran","family":"Makunts","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sama","family":"Alpatty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly C.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rabia S.","family":"Atayee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben","family":"Abagyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,21]]},"reference":[{"key":"53622_CR1","doi-asserted-by":"publisher","unstructured":"Song, H., Zhu, J. & Lu, D. Long-term proton pump inhibitor (PPI) use and the development of gastric pre-malignant lesions. Cochrane Database Syst Rev, CD010623, https:\/\/doi.org\/10.1002\/14651858.CD010623.pub2 (2014).","DOI":"10.1002\/14651858.CD010623.pub2"},{"key":"53622_CR2","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1111\/j.1365-2036.1991.tb00025.x","volume":"5","author":"W Londong","year":"1991","unstructured":"Londong, W. et al. Dose-related healing of duodenal ulcer with the proton pump inhibitor lansoprazole. Aliment Pharmacol Ther 5, 245\u2013254 (1991).","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"53622_CR3","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1038\/ajg.2012.444","volume":"108","author":"Philip O Katz","year":"2013","unstructured":"Katz, P. O., Gerson, L. B. & Vela, M. F. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol 108, 308\u2013328; quiz 329, https:\/\/doi.org\/10.1038\/ajg.2012.444 (2013).","journal-title":"American Journal of Gastroenterology"},{"key":"53622_CR4","doi-asserted-by":"publisher","first-page":"15","DOI":"10.2165\/00003495-198632010-00002","volume":"32","author":"SP Clissold","year":"1986","unstructured":"Clissold, S. P. & Campoli-Richards, D. M. Omeprazole. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peptic ulcer disease and Zollinger-Ellison syndrome. Drugs 32, 15\u201347 (1986).","journal-title":"Drugs"},{"key":"53622_CR5","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1056\/NEJM198901123200201","volume":"320","author":"A Walan","year":"1989","unstructured":"Walan, A. et al. Effect of omeprazole and ranitidine on ulcer healing and relapse rates in patients with benign gastric ulcer. N Engl J Med 320, 69\u201375, https:\/\/doi.org\/10.1056\/NEJM198901123200201 (1989).","journal-title":"N Engl J Med"},{"key":"53622_CR6","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1001\/jama.2015.13766","volume":"314","author":"ED Kantor","year":"2015","unstructured":"Kantor, E. D., Rehm, C. D., Haas, J. S., Chan, A. T. & Giovannucci, E. L. Trends in Prescription Drug Use Among Adults in the United States From 1999\u20132012. JAMA 314, 1818\u20131831, https:\/\/doi.org\/10.1001\/jama.2015.13766 (2015).","journal-title":"JAMA"},{"key":"53622_CR7","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1007\/s11894-008-0098-4","volume":"10","author":"JM Shin","year":"2008","unstructured":"Shin, J. M. & Sachs, G. Pharmacology of proton pump inhibitors. Curr Gastroenterol Rep 10, 528\u2013534 (2008).","journal-title":"Curr Gastroenterol Rep"},{"key":"53622_CR8","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/s00424-008-0495-4","volume":"457","author":"JM Shin","year":"2009","unstructured":"Shin, J. M., Munson, K., Vagin, O. & Sachs, G. The gastric HK-ATPase: structure, function, and inhibition. Pflugers Arch 457, 609\u2013622, https:\/\/doi.org\/10.1007\/s00424-008-0495-4 (2009).","journal-title":"Pflugers Arch"},{"key":"53622_CR9","unstructured":"Prilosec (omeprazole) Label \u2013 FDA, https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/019810s096lbl.pdf (2012)."},{"key":"53622_CR10","unstructured":"Prevacid (lansoprazole) Label \u2013 FDA, https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/020406s078-021428s025lbl.pdf (2012)."},{"key":"53622_CR11","unstructured":"Nexium (esomeprazole magnesium) Label \u2013 FDA, https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/022101s014021957s017021153s050lbl.pdf (2014)."},{"key":"53622_CR12","unstructured":"Protonix (pantoprazole sodium) Label \u2013 FDA, https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/020987s045lbl.pdf (2012)"},{"key":"53622_CR13","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1046\/j.1525-1594.1998.06200.x","volume":"22","author":"P Hardy","year":"1998","unstructured":"Hardy, P. et al. Inhibition of gastric secretion by omeprazole and efficiency of calcium carbonate on the control of hyperphosphatemia in patients on chronic hemodialysis. Artif Organs 22, 569\u2013573 (1998).","journal-title":"Artif Organs"},{"key":"53622_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-39335-7","volume":"9","author":"T Makunts","year":"2019","unstructured":"Makunts, T., Cohen, I. V., Awdishu, L. & Abagyan, R. Analysis of postmarketing safety data for proton-pump inhibitors reveals increased propensity for renal injury, electrolyte abnormalities, and nephrolithiasis. Scientific Reports 9, 2282, https:\/\/doi.org\/10.1038\/s41598-019-39335-7 (2019).","journal-title":"Scientific Reports"},{"key":"53622_CR15","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1001\/jamainternmed.2015.7193","volume":"176","author":"B Lazarus","year":"2016","unstructured":"Lazarus, B. et al. Proton Pump Inhibitor Use and the Risk of Chronic Kidney Disease. JAMA Intern Med 176, 238\u2013246, https:\/\/doi.org\/10.1001\/jamainternmed.2015.7193 (2016).","journal-title":"JAMA Intern Med"},{"key":"53622_CR16","doi-asserted-by":"publisher","first-page":"3153","DOI":"10.1681\/ASN.2015121377","volume":"27","author":"Y Xie","year":"2016","unstructured":"Xie, Y. et al. Proton Pump Inhibitors and Risk of Incident CKD and Progression to ESRD. J Am Soc Nephrol 27, 3153\u20133163, https:\/\/doi.org\/10.1681\/ASN.2015121377 (2016).","journal-title":"J Am Soc Nephrol"},{"key":"53622_CR17","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1038\/nrendo.2012.170","volume":"8","author":"C Wilson","year":"2012","unstructured":"Wilson, C. Bone: proton-pump inhibitors and fractures. Nat Rev Endocrinol 8, 625, https:\/\/doi.org\/10.1038\/nrendo.2012.170 (2012).","journal-title":"Nat Rev Endocrinol"},{"key":"53622_CR18","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1038\/ajg.2012.179","volume":"107","author":"S Janarthanan","year":"2012","unstructured":"Janarthanan, S., Ditah, I., Adler, D. G. & Ehrinpreis, M. N. Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: a meta-analysis. Am J Gastroenterol 107, 1001\u20131010, https:\/\/doi.org\/10.1038\/ajg.2012.179 (2012).","journal-title":"Am J Gastroenterol"},{"key":"53622_CR19","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s00406-014-0554-0","volume":"265","author":"B Haenisch","year":"2015","unstructured":"Haenisch, B. et al. Risk of dementia in elderly patients with the use of proton pump inhibitors. Eur Arch Psychiatry Clin Neurosci 265, 419\u2013428, https:\/\/doi.org\/10.1007\/s00406-014-0554-0 (2015).","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"53622_CR20","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1001\/jamaneurol.2015.4791","volume":"73","author":"W Gomm","year":"2016","unstructured":"Gomm, W. et al. Association of Proton Pump Inhibitors With Risk of Dementia: A Pharmacoepidemiological Claims Data Analysis. JAMA Neurol 73, 410\u2013416, https:\/\/doi.org\/10.1001\/jamaneurol.2015.4791 (2016).","journal-title":"JAMA Neurol"},{"key":"53622_CR21","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1111\/jgs.14956","volume":"65","author":"FC Goldstein","year":"2017","unstructured":"Goldstein, F. C. et al. Proton Pump Inhibitors and Risk of Mild Cognitive Impairment and Dementia. J Am Geriatr Soc 65, 1969\u20131974, https:\/\/doi.org\/10.1111\/jgs.14956 (2017).","journal-title":"J Am Geriatr Soc"},{"key":"53622_CR22","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1017\/S1041610215002082","volume":"28","author":"A Booker","year":"2016","unstructured":"Booker, A., Jacob, L. E., Rapp, M., Bohlken, J. & Kostev, K. Risk factors for dementia diagnosis in German primary care practices. Int Psychogeriatr 28, 1059\u20131065, https:\/\/doi.org\/10.1017\/S1041610215002082 (2016).","journal-title":"Int Psychogeriatr"},{"issue":"Suppl 3","key":"53622_CR23","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1097\/00002093-199404000-00015","volume":"8","author":"MP Lawton","year":"1994","unstructured":"Lawton, M. P. Quality of life in Alzheimer disease. Alzheimer Dis Assoc Disord 8(Suppl 3), 138\u2013150 (1994).","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"53622_CR24","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1093\/geront\/29.1.8","volume":"29","author":"MP Lawton","year":"1989","unstructured":"Lawton, M. P., Brody, E. M. & Saperstein, A. R. A controlled study of respite service for caregivers of Alzheimer\u2019s patients. Gerontologist 29, 8\u201316 (1989).","journal-title":"Gerontologist"},{"key":"53622_CR25","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1038\/nm0706-780","volume":"12","author":"C Mount","year":"2006","unstructured":"Mount, C. & Downton, C. Alzheimer disease: progress or profit? Nat Med 12, 780\u2013784, https:\/\/doi.org\/10.1038\/nm0706-780 (2006).","journal-title":"Nat Med"},{"key":"53622_CR26","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1590\/S1980-57642010DN40400003","volume":"4","author":"DM Castro","year":"2010","unstructured":"Castro, D. M., Dillon, C., Machnicki, G. & Allegri, R. F. The economic cost of Alzheimer\u2019s disease: Family or public health burden? Dement Neuropsychol 4, 262\u2013267, https:\/\/doi.org\/10.1590\/S1980-57642010DN40400003 (2010).","journal-title":"Dement Neuropsychol"},{"key":"53622_CR27","first-page":"39","volume":"2","author":"TS Dharmarajan","year":"2009","unstructured":"Dharmarajan, T. S. & Gunturu, S. G. Alzheimer\u2019s disease: a healthcare burden of epidemic proportion. Am Health Drug Benefits 2, 39\u201347 (2009).","journal-title":"Am Health Drug Benefits"},{"key":"53622_CR28","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1177\/2042098613482484","volume":"4","author":"JJ Heidelbaugh","year":"2013","unstructured":"Heidelbaugh, J. J. Proton pump inhibitors and risk of vitamin and mineral deficiency: evidence and clinical implications. Ther Adv Drug Saf 4, 125\u2013133, https:\/\/doi.org\/10.1177\/2042098613482484 (2013).","journal-title":"Ther Adv Drug Saf"},{"key":"53622_CR29","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.jclinepi.2003.08.015","volume":"57","author":"RJ Valuck","year":"2004","unstructured":"Valuck, R. J. & Ruscin, J. M. A case-control study on adverse effects: H2 blocker or proton pump inhibitor use and risk of vitamin B12 deficiency in older adults. J Clin Epidemiol 57, 422\u2013428, https:\/\/doi.org\/10.1016\/j.jclinepi.2003.08.015 (2004).","journal-title":"J Clin Epidemiol"},{"key":"53622_CR30","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.1001\/jama.2013.280490","volume":"310","author":"JR Lam","year":"2013","unstructured":"Lam, J. R., Schneider, J. L., Zhao, W. & Corley, D. A. Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency. JAMA 310, 2435\u20132442, https:\/\/doi.org\/10.1001\/jama.2013.280490 (2013).","journal-title":"JAMA"},{"key":"53622_CR31","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/0022-510X(84)90147-3","volume":"66","author":"PA McCombe","year":"1984","unstructured":"McCombe, P. A. & McLeod, J. G. The peripheral neuropathy of vitamin B12 deficiency. J Neurol Sci 66, 117\u2013126 (1984).","journal-title":"J Neurol Sci"},{"key":"53622_CR32","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.neucli.2005.12.001","volume":"35","author":"G Sakly","year":"2005","unstructured":"Sakly, G., Hellara, O., Trabelsi, A. & Dogui, M. [Reversible peripheral neuropathy induced by vitamin B12 deficiency]. Neurophysiol Clin 35, 149\u2013153, https:\/\/doi.org\/10.1016\/j.neucli.2005.12.001 (2005).","journal-title":"Neurophysiol Clin"},{"key":"53622_CR33","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1002\/mus.20155","volume":"31","author":"YA Rajabally","year":"2005","unstructured":"Rajabally, Y. A. & Jacob, S. Neuropathy associated with lansoprazole treatment. Muscle Nerve 31, 124\u2013125, https:\/\/doi.org\/10.1002\/mus.20155 (2005).","journal-title":"Muscle Nerve"},{"key":"53622_CR34","doi-asserted-by":"publisher","first-page":"456","DOI":"10.4103\/0972-5229.136075","volume":"18","author":"AK Wang","year":"2014","unstructured":"Wang, A. K., Sharma, S., Kim, P. & Mrejen-Shakin, K. Hypomagnesemia in the intensive care unit: Choosing your gastrointestinal prophylaxis, a case report and review of the literature. Indian J Crit Care Med 18, 456\u2013460, https:\/\/doi.org\/10.4103\/0972-5229.136075 (2014).","journal-title":"Indian J Crit Care Med"},{"key":"53622_CR35","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1097\/AUD.0000000000000347","volume":"38","author":"BM Lin","year":"2017","unstructured":"Lin, B. M. et al. Prospective Study of Gastroesophageal Reflux, Use of Proton Pump Inhibitors and H2-Receptor Antagonists, and Risk of Hearing Loss. Ear Hear 38, 21\u201327, https:\/\/doi.org\/10.1097\/AUD.0000000000000347 (2017).","journal-title":"Ear Hear"},{"key":"53622_CR36","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1001\/archoto.2010.222","volume":"137","author":"ED McCoul","year":"2011","unstructured":"McCoul, E. D. et al. A prospective study of the effect of gastroesophageal reflux disease treatment on children with otitis media. Arch Otolaryngol Head Neck Surg 137, 35\u201341, https:\/\/doi.org\/10.1001\/archoto.2010.222 (2011).","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"53622_CR37","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1001\/jamaoto.2014.3581","volume":"141","author":"RC O\u2019Reilly","year":"2015","unstructured":"O\u2019Reilly, R. C. et al. The role of gastric pepsin in the inflammatory cascade of pediatric otitis media. JAMA Otolaryngol Head Neck Surg 141, 350\u2013357, https:\/\/doi.org\/10.1001\/jamaoto.2014.3581 (2015).","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"issue":"811\u2013812","key":"53622_CR38","first-page":"814","volume":"8","author":"S Trevisani","year":"2012","unstructured":"Trevisani, S. & Cereda, J. M. Blurred vision: a rare secondary effect of proton pump inhibitors. Rev Med Suisse 8(811\u2013812), 814 (2012).","journal-title":"Rev Med Suisse"},{"key":"53622_CR39","first-page":"575","volume":"97","author":"M Kohno","year":"2000","unstructured":"Kohno, M. et al. Two cases of ocular damage associated with proton pump inhibitors. Nihon Shokakibyo Gakkai Zasshi 97, 575\u2013579 (2000).","journal-title":"Nihon Shokakibyo Gakkai Zasshi"},{"key":"53622_CR40","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1136\/bmj.314.7097.1805","volume":"314","author":"PS Sch\u00f6nh\u00f6fer","year":"1997","unstructured":"Sch\u00f6nh\u00f6fer, P. S., Werner, B. & Tr\u00f6ger, U. Ocular damage associated with proton pump inhibitors. BMJ 314, 1805 (1997).","journal-title":"BMJ"},{"key":"53622_CR41","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1016\/S0140-6736(95)90805-6","volume":"345","author":"LA Garc\u00eda Rodr\u00edguez","year":"1995","unstructured":"Garc\u00eda Rodr\u00edguez, L. A., Mannino, S. & Wallander, M. A. Ocular safety of antiulcer drugs. Lancet 345, 1059\u20131060 (1995).","journal-title":"Lancet"},{"key":"53622_CR42","doi-asserted-by":"publisher","first-page":"537","DOI":"10.2147\/JPR.S88207","volume":"8","author":"CD Malone","year":"2015","unstructured":"Malone, C. D., Bhowmick, A. & Wachholtz, A. B. Migraine: treatments, comorbidities, and quality of life, in the USA. J Pain Res 8, 537\u2013547, https:\/\/doi.org\/10.2147\/JPR.S88207 (2015).","journal-title":"J Pain Res"},{"key":"53622_CR43","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1111\/j.1468-2982.1998.1809638.x","volume":"18","author":"MJ Monz\u00f3n","year":"1998","unstructured":"Monz\u00f3n, M. J. & L\u00e1inez, M. J. Quality of life in migraine and chronic daily headache patients. Cephalalgia 18, 638\u2013643, https:\/\/doi.org\/10.1111\/j.1468-2982.1998.1809638.x (1998).","journal-title":"Cephalalgia"},{"key":"53622_CR44","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1177\/0333102414535114","volume":"35","author":"JF Liang","year":"2015","unstructured":"Liang, J. F. et al. Proton pump inhibitor-related headaches: a nationwide population-based case-crossover study in Taiwan. Cephalalgia 35, 203\u2013210, https:\/\/doi.org\/10.1177\/0333102414535114 (2015).","journal-title":"Cephalalgia"},{"key":"53622_CR45","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.yebeh.2016.06.039","volume":"62","author":"ME S\u00e1ez","year":"2016","unstructured":"S\u00e1ez, M. E. et al. Risk of seizure associated with use of acid-suppressive drugs: An observational cohort study. Epilepsy Behav 62, 72\u201380, https:\/\/doi.org\/10.1016\/j.yebeh.2016.06.039 (2016).","journal-title":"Epilepsy Behav"},{"key":"53622_CR46","doi-asserted-by":"publisher","first-page":"632721","DOI":"10.1155\/2012\/632721","volume":"2012","author":"NY Gandhi","year":"2012","unstructured":"Gandhi, N. Y., Sharif, W. K., Chadha, S. & Shakher, J. A patient on long-term proton pump inhibitors develops sudden seizures and encephalopathy: an unusual presentation of hypomagnesaemia. Case Rep Gastrointest Med 2012, 632721, https:\/\/doi.org\/10.1155\/2012\/632721 (2012).","journal-title":"Case Rep Gastrointest Med"},{"key":"53622_CR47","doi-asserted-by":"publisher","first-page":"104","DOI":"10.4158\/EP10241.CR","volume":"17","author":"S Milman","year":"2011","unstructured":"Milman, S. & Epstein, E. J. Proton pump inhibitor-induced hypocalcemic seizure in a patient with hypoparathyroidism. Endocr Pract 17, 104\u2013107, https:\/\/doi.org\/10.4158\/EP10241.CR (2011).","journal-title":"Endocr Pract"},{"key":"53622_CR48","doi-asserted-by":"publisher","first-page":"591","DOI":"10.7861\/clinmedicine.11-6-591","volume":"11","author":"N Arulanantham","year":"2011","unstructured":"Arulanantham, N., Anderson, M., Gittoes, N. & Ferner, R. E. A 63-year-old man with hypomagnesaemia and seizures. Clin Med (Lond) 11, 591\u2013593 (2011).","journal-title":"Clin Med (Lond)"},{"key":"53622_CR49","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1080\/14740338.2017.1323867","volume":"16","author":"YM Alatawi","year":"2017","unstructured":"Alatawi, Y. M. & Hansen, R. A. Empirical estimation of under-reporting in the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS). Expert Opin Drug Saf 16, 761\u2013767, https:\/\/doi.org\/10.1080\/14740338.2017.1323867 (2017).","journal-title":"Expert Opin Drug Saf"},{"key":"53622_CR50","doi-asserted-by":"publisher","unstructured":"Maciejewski, M. et al. Reverse translation of adverse event reports paves the way for de-risking preclinical off-targets. Elife 6, https:\/\/doi.org\/10.7554\/eLife.25818 (2017).","DOI":"10.7554\/eLife.25818"},{"key":"53622_CR51","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","volume":"10","author":"T Sakaeda","year":"2013","unstructured":"Sakaeda, T., Tamon, A., Kadoyama, K. & Okuno, Y. Data mining of the public version of the FDA Adverse Event Reporting System. Int J Med Sci 10, 796\u2013803, https:\/\/doi.org\/10.7150\/ijms.6048 (2013).","journal-title":"Int J Med Sci"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-53622-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-53622-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-53622-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T16:18:11Z","timestamp":1671293891000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-53622-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,21]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["53622"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-53622-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,21]]},"assertion":[{"value":"16 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. Lee is a consultant for Takeda and Otsuka America Pharmaceutical, Inc. Other authors declare no conflict of financial or non-financial interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17280"}}